Filing Analysis
Aytu BioPharma, Inc. has mutually terminated its exclusive license agreement (the 'Metadate Agreement') with Lannett Company, Inc., effective June 23, 2026. The company retains rights to sell existing inventory and fulfill remaining royalty obligations.
🚩 Red Flags
- Loss of an exclusive licensing agreement can impact long-term revenue streams and market exclusivity.
- The termination of a previously amended agreement (most recently July 2025) suggests potential friction or strategic shifts in the partnership.
📋 Key Facts
- The Metadate Agreement was originally entered into on May 11, 2022, with subsequent amendments in July 2023 and July 2025.
- Termination became effective as of June 23, 2026.
- Aytu BioPharma retains the right to sell and distribute existing inventory at its sole discretion.
- The company must continue providing royalty reports and paying royalties until all existing inventory sales cease.
- Metadate CD® reported $49,000 in net revenue for the quarter ended March 31, 2026.
Aytu BioPharma, Inc. reported its fiscal 2026 third quarter financial and operational results on May 13, 2026. The company hosted a conference call and webcast to discuss the performance and provide updates.
📋 Key Facts
- Announced fiscal 2026 third quarter results on May 13, 2026.
- Scheduled a conference call and live audio webcast for May 13, 2026, at 4:30 p.m. Eastern time.
- The press release was furnished as Exhibit 99.1 under Item 2.02.
Aytu BioPharma amended warrant agreements from 2023 and 2025 to resolve an accounting ambiguity that forced the company to classify the warrants as liabilities. By clarifying that stockholders cannot vote to amend beneficial ownership blockers, the company expects to reclassify approximately $25.2 million from liabilities to equity.
🚩 Red Flags
- Technical accounting error regarding warrant classification led to significant liability reporting ($25.2 million).
- The filing involves multiple 8-K items (1.01, 2.02, 3.02, 3.03), indicating a complex modification of financial instruments.
📋 Key Facts
- The company identified accounting errors in the classification of June 2023 and June 2025 warrants under ASC Topic 480 and ASC Topic 815.
- Warrant liabilities were recorded at $18.1 million for the quarter ended September 30, 2025, and $25.2 million for the quarter ended December 31, 2025.
- On March 31, 2026, the company entered into amended and restated warrant agreements for the 2023 Prefunded, 2023 Tranche A, and 2025 Prefunded warrants.
- The amendments clarify that a vote of stockholders cannot amend or change the beneficial ownership blockers.
- The company expects the amendment to reduce warrant liabilities and increase equity value by the same amount on future financial statements.
Aytu BioPharma, Inc. has filed an 8-K to announce its fiscal 2026 second quarter operational and financial results via a press release.
📋 Key Facts
- The company issued a press release on February 3, 2026, regarding Q2 2026 results.
- A conference call and live audio webcast were scheduled for February 3, 2026, at 4:30 p.m. ET to discuss the results.
- The press release is furnished as Exhibit 99.1 and is not considered 'filed' material under Section 18 of the Exchange Act.
Aytu BioPharma, Inc. issued an 8-K to provide notice of a press release and presentation following its Investor Day held on January 20, 2026. The disclosure primarily focuses on the company's EXXUA™ (gepirone) extended-release tablets opportunity.
📋 Key Facts
- Company held an 'Investor Day' on January 20, 2026.
- The filing includes a press release recapping the event (Exhibit 99.1).
- The filing includes an investor presentation used during the meeting (Exhibit 99.2).
- Key focus of the presentation is the EXXUA™ (gepirone) extended-release tablets opportunity.
Aytu BioPharma, Inc. held its 2026 Annual Meeting of Stockholders on December 10, 2025. The meeting resulted in the reelection of all incumbent directors and the ratification of Grant Thornton LLP as the independent auditor.
🚩 Red Flags
- High number of 'Broker Non-Votes' (approx. 2.5M shares) across all proposals suggests a significant portion of the float is held by institutional or non-voting beneficial owners, though this is common in micro-caps.
📋 Key Facts
- The 2026 Annual Meeting was held on December 10, 2025.
- Quorum was established with 6,083,713 shares present (approx. 60% of total issued and outstanding).
- All five incumbent directors—Joshua R. Disbrow, John A. Donofrio, Jr., Carl C. Dockery, Abhinav Jain, and Vivian H. Liu—were reelected by a majority vote.
- Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026.
- The non-binding advisory vote on executive compensation was approved.
Aytu BioPharma, Inc. has filed an 8-K to announce the release of its fiscal 2026 first quarter operational and financial results.
📋 Key Facts
- The company issued a press release on November 13, 2025, regarding Q1 2026 results.
- A conference call and live audio webcast were scheduled for November 13, 2025, at 4:30 p.m. ET to discuss the results.
- The financial results are furnished as Exhibit 99.1.
Aytu BioPharma, Inc. announced its fiscal 2025 full year and fourth quarter operational and financial results via a press release on September 23, 2025.
📋 Key Facts
- Company released fiscal 2025 full year and Q4 operational and financial results.
- The announcement included a scheduled conference call and live audio webcast for September 23, 2025, at 4:30 p.m. ET.
- Results were furnished as Exhibit 99.1.
Aytu BioPharma has completed the transfer of all rights, title, and interest in its AR101 asset to EnzCo, LLC. This action effectively terminates a previous asset purchase agreement with Rumpus entities and follows the company's decision to suspend clinical development of AR101.
🚩 Red Flags
- Asset abandonment: The company has suspended clinical development of AR101 and is divesting the rights entirely.
- Loss of pipeline asset: Transferring all interest in a drug candidate suggests a strategic retreat or lack of capital to continue development.
📋 Key Facts
- On August 5, 2025, Aytu BioPharma reached terms to transfer all rights, title, and interest in AR101 to EnzCo, LLC.
- The transaction includes mutual consideration and releases between the parties.
- The transfer extinguishes and terminates all obligations under the April 21, 2021 asset purchase agreement with Rumpus entities.
- There are no penalties or remaining obligations for Aytu BioPharma resulting from this termination.
Aytu BioPharma entered into Amendment No. 6 to its Loan and Security Agreement, extending the maturity dates of its term loan and revolving credit facility to June 12, 2029. The amendment includes an increase in the Eclipse Term Loan principal to $13.0 million and provides for a $1.5 million incremental advance under the revolving facility.
🚩 Red Flags
- The need for an amendment to extend maturities and increase debt suggests ongoing liquidity management needs common in micro-cap biotech.
- Incremental advance requires mandatory monthly repayments of $125,000 starting August 2025, creating a fixed cash outflow.
📋 Key Facts
- Amendment No. 6 to Loan and Security Agreement signed on June 20, 2025.
- Term loan maturity extended to June 12, 2029.
- Revolving credit facility maturity extended to June 12, 2029.
- Eclipse Term Loan principal increased to $13.0 million as of the closing date.
- Provided for a $1.5 million incremental advance under the revolving loan at SOFR + 5.50%.
- Repayment of the $1.5 million incremental advance begins August 1, 2025, at $125,000 per month until fully repaid.
Aytu BioPharma, Inc. has released an updated investor presentation via its website to support upcoming investor meetings. The update specifically highlights the EXXUA™ (gepirone) extended-release tablets opportunity.
📋 Key Facts
- Company posted an updated investor presentation on June 17, 2025.
- The presentation focuses on the EXXUA™ (gepirone) extended-release tablets opportunity.
- Presentation is intended for use in upcoming investor meetings.
Aytu BioPharma, Inc. announced the closing of a public offering of common stock and provided updates regarding its EXXUA™ (gepirone) extended-release tablets commercialization plan.
🚩 Red Flags
- Dilution: The closing of a public offering typically results in share dilution for existing shareholders.
📋 Key Facts
- Public offering of common stock has closed as of June 9, 2025.
- Total shares issued and outstanding following the offering: 8,976,914 shares.
- Company scheduled a conference call for June 11, 2025, to discuss EXXUA™ commercialization.
- The filing includes details regarding the EXXUA™ (gepirone) opportunity.
Aytu BioPharma, Inc. entered into an underwriting agreement to conduct a public offering of common stock and prefunded warrants to raise approximately $12.9 million to $14.9 million in net proceeds.
🚩 Red Flags
- Significant dilution via the issuance of over 8 million prefunded warrants which are nearly equivalent to the total common stock being offered.
📋 Key Facts
- Offering size: 1,366,668 shares of common stock at $1.50 per share.
- Prefunded Warrants: 8,233,332 warrants at $1.4999 each (enabling purchase of one share at $0.0001).
- Underwriter: Lake Street Capital Markets, LLC.
- Expected net proceeds: ~$12.9 million (up to ~$14.9 million if option is exercised).
- Use of proceeds: General corporate purposes, working capital, and commercialization of EXXUA (gepirone) extended-release tablets.
- Closing date expected on or about June 9, 2025.
Aytu BioPharma entered into an exclusive commercialization agreement with Fabre-Kramer Holdings for EXXUA (gepirone), an FDA-approved treatment for Major Depressive Disorder. The company plans to launch the product in Q4 2025.
🚩 Red Flags
- Significant contingent liabilities: The company faces substantial milestone payments and high royalty rates (up to 39%) which could compress margins significantly during high-growth phases.
📋 Key Facts
- Agreement date: June 5, 2025
- Upfront cash payment of $3,000,000 made on effective date
- Second payment of $3,000,000 due within 45 days of the one-year anniversary of first physical sale (potential increase to $5M if year 1 net sales $\ge$ $35M)
- Milestone payments ranging from $5M to over $100M per year based on sales thresholds
- Royalty structure: Initially 28% of net sales, increasing to 39% if annual net sales exceed $300M
- Product (EXXUA) is an FDA-approved treatment for Major Depressive Disorder (MDD)
- Anticipated launch in the US market in Q4 2025
Aytu BioPharma, Inc. held its 2025 Annual Meeting of stockholders on May 21, 2025. The meeting resulted in the reelection of all incumbent directors and approval of several key proposals, including an amendment to the company's equity incentive plan.
📋 Key Facts
- The 2025 Annual Meeting saw a quorum representing approximately 70% of total issued and outstanding shares (4,329,439 shares present).
- Stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing reserved shares by 300,000 to reach a total of 500,000 shares.
- All incumbent directors (Joshua R. Disbrow, John A. Donofrio, Jr., Carl C. Dockery, Abhinav Jain, and Vivian H. Liu) were reelected by majority vote.
- Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2025.
- A non-binding advisory vote on executive compensation was approved.
Aytu BioPharma, Inc. announced its fiscal 2025 third quarter operational and financial results via a press release on May 14, 2025.
📋 Key Facts
- Company issued a press release regarding fiscal 2025 Q3 operational and financial results.
- A conference call and live audio webcast were scheduled for May 14, 2025, at 4:30 p.m. ET to discuss the results.
- The filing includes Exhibit 99.1 containing the press release.
Aytu BioPharma, Inc. has filed an 8-K to announce the release of its fiscal 2025 second quarter operational and financial results via a press release.
📋 Key Facts
- The company issued a press release on February 12, 2025, regarding Q2 2025 results.
- A conference call and live audio webcast were scheduled for February 12, 2025, at 4:30 p.m. ET to discuss the results.
- The filing includes Exhibit 99.1 containing the press release.
Aytu BioPharma announced that the settlement of certain derivative claims in the Witmer v. Armistice Capital, LLC et al action is scheduled for a court approval hearing on January 13, 2025.
🚩 Red Flags
- Ongoing litigation/derivative action (though reaching settlement phase)
📋 Key Facts
- The matter involves a derivative claim: Witmer v. Armistice Capital, LLC et al.
- A settlement has already been reached and disclosed previously.
- A court approval hearing is scheduled for January 13, 2025, in the Delaware Chancery Court.
Aytu BioPharma, Inc. announced the termination of its Chief Financial Officer, Mark K. Oki, and the simultaneous appointment of Ryan Selhorn as the new CFO. The company also reported a separation agreement for Mr. Oki involving a $499,590 severance payment.
🚩 Red Flags
- Sudden termination of the CFO (Mark K. Oki) can sometimes signal internal friction or disagreements over financial reporting.
- Significant cash outflow for severance ($499,590) in a micro-cap context.
📋 Key Facts
- Mark K. Oki was terminated as CFO effective November 11, 2024; he will consult through December 1, 2024.
- Ryan Selhorn appointed as CFO, Corporate Secretary, and Treasurer on November 11, 2024.
- Separation payment for Mark K. Oki is $499,590, to be paid over 12 months.
- New CFO Ryan Selhorn's base salary is set at $400,000 with a 40% target bonus.
- The Board separated the roles of Chairman and CEO; John A. Donofrio, Jr. was appointed Chairman on November 6, 2024.
Aytu BioPharma, Inc. has entered into an exclusive agreement with Lupin Pharma Canada Ltd to commercialize two of its products, Adzenys XR-ODT® and Cotempla XR-ODT®, within the Canadian market.
📋 Key Facts
- Exclusive agreement signed with Lupin Pharma Canada Ltd.
- Products covered: Adzenys XR-ODT® and Cotempla XR-ODT®.
- Territory: Canada.
- Filing date: October 1, 2024.
Aytu BioPharma, Inc. filed an 8-K to announce the release of its fiscal 2024 full year and fourth quarter operational and financial results.
📋 Key Facts
- The filing was made on September 26, 2024.
- Company announced fiscal 2024 full year and Q4 results via press release.
- A conference call and webcast were scheduled for September 26, 2024, at 4:30 p.m. ET to discuss the results.
Aytu BioPharma, Inc. announced the sale of its Consumer Health business following a wind-down of those operations. This represents a significant strategic shift and divestiture of a business segment.
🚩 Red Flags
- Divestiture of an entire business segment often indicates a need for liquidity or a failed strategic direction in that sector.
- The mention of 'wind down' prior to the sale suggests operational cessation before the transaction was finalized, which can be a sign of distress.
📋 Key Facts
- Company issued a press release on August 6, 2024, regarding the sale of its Consumer Health business.
- The sale follows a prior wind-down of Consumer Health operations.
- The filing is made under Item 7.01 (Regulation FD Disclosure) and includes Exhibit 99.1.
Aytu BioPharma, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 26, 2024. All three proposals—election of directors, ratification of auditors, and advisory vote on executive compensation—were approved by shareholders.
📋 Key Facts
- The meeting was held on June 26, 2024.
- Quorum consisted of approximately 73% of total issued and outstanding shares (4,037,162 shares).
- All five incumbent directors were re-elected by a majority vote: Joshua R. Disbrow, John A. Donofrio, Jr., Carl C. Dockery, Abhinav Jain, and Vivian H. Liu.
- Stockholders ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending June 30, 2024.
- The non-binding advisory vote on executive compensation was approved.
Aytu BioPharma entered into a significant new financing agreement with Eclipse Business Capital LLC, involving a $13.0 million term loan and an extension/increase of its revolving credit facility. The proceeds were used to repay existing debt obligations under the Avenue Facility Agreement.
🚩 Red Flags
- High interest rate environment (SOFR + 7.0%) indicates significant cost of capital.
- Debt restructuring/refinancing activity often suggests liquidity management needs in micro-cap biotech firms.
- The use of proceeds to repay existing debt rather than funding R&D or operations is a neutral-to-negative indicator for growth.
📋 Key Facts
- Entered into 'Eclipse Consent, Joinder and Amendment No. 5' on June 12, 2024.
- Secured a $13.0 million term loan from Eclipse Business Capital LLC.
- Term loan interest rate is SOFR + 7.0% with a four-year term.
- Revolving credit facility maturity extended by four years; maximum borrowing capacity increased to $14.5 million via Second Amended and Restated Revolving Note.
- Proceeds used to fully repay Avenue Debt Obligations under the January 26, 2022, Loan and Security Agreement.
- As of June 18, 2024, the Company had 5,972,327 shares of common stock outstanding.
Aytu BioPharma, Inc. filed an 8-K to announce the release of its operational and financial results for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- The filing reports on results of operations and financial condition for the quarter ending March 31, 2024.
- A press release was issued on May 15, 2024, containing the detailed financial data (Exhibit 99.1).
- The company held a conference call and webcast on May 15, 2024, to discuss these results.
Aytu BioPharma, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended December 31, 2023. The filing serves as a formal notice that the company has issued a press release regarding its operational and financial performance.
📋 Key Facts
- Reporting period: Fiscal quarter ended December 31, 2023.
- Filing date: February 14, 2024.
- The company held/scheduled a conference call and webcast on February 14, 2024, to discuss results.